Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: A pooled analysis of randomized trials
Volume 8, Issue 8
Downloads and Tools
Pages 1036 - 1041http://dx.doi.org/10.4161/hv.20357
: Haemophilus influenzae type b, MMR, Neisseria meningitidis serogroups C and Y, toddlers, vaccination, varicella
Authors: Kristina A. Bryant, Jodie McVernon, Colin D. Marchant, Terry Nolan, Gary S. Marshall, Peter Richmond, Helen Marshall, Michael Nissen, Stephen B. Lambert, Emmanuel Aris, Narcisa Mesaros and Jacqueline M. Miller View affiliations
A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjugated to N. meningitidis outer membrane protein) coadministered with measles-mumps-rubella (MMR) and varicella (VAR) vaccines (NCT00134719/NCT00289783). Noninferiority of immunological responses to MMR and VAR was demonstrated between groups and incidences of MMR- and VAR-specific solicited symptoms were similar, indicating that HibMenCY-TT can be coadministered with MMR and VAR.
Received: November 30, 2011; Accepted: April 12, 2012; Published Online: August 1, 2012